Latest Articles about ITMN

InterMune Cuts Loss, Affirms View - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 19:10:49 Z

InterMune Inc .'s ( ITMN ) first-quarter loss per share of 66 cents was narrower than the Zacks Consensus Estimate of a loss of 76 cents and the year-ago loss of 75 cents per share. The

Mid-Morning Market Update: Markets Tumble, Oracle Posts Downbeat Results

Jake L'Ecuyer — Thu, 21 Mar 2013 18:41:28 Z

Following the market opening Thursday, the Dow traded down 0.38 percent to 14,456.47 while the NASDAQ dropped 0.65 percent to 3,232.90. The S&P also fell, dropping 0.45 percent to

Wider Loss at InterMune - Analyst Blog

Zacks Equity Research — Fri, 22 Feb 2013 22:30:01 Z

InterMune Inc. 's ( ITMN ) fourth-quarter loss per share of 91 cents was wider than the Zacks Consensus Estimate of a loss of 86 cents and the year-ago loss of 73 cents per share. The wider

InterMune Prices Public Offerings - Analyst Blog

Zacks Equity Research — Sat, 19 Jan 2013 01:40:01 Z

InterMune Inc. ( ITMN ) recently priced its concurrent underwritten public offerings of convertible senior notes and shares of its common stock, announced earlier this week. InterMune has

InterMune to Raise Funds - Analyst Blog

Zacks Equity Research — Thu, 17 Jan 2013 02:50:01 Z

InterMune Inc. ( ITMN ) recently announced its intention to raise funds through concurrent underwritten public offerings. InterMune intends to offer convertible senior notes (due 2017) of

Loss at ITMN Narrower than Expected - Analyst Blog

Zacks Equity Research — Thu, 08 Nov 2012 21:00:01 Z

InterMune Inc. 's ( ITMN ) third-quarter loss per share of 70 cents was narrower than the Zacks Consensus loss Estimate of 84 cents. The narrower than expected loss was primarily

InterMune's Esbriet OK'd in Canada - Analyst Blog

Zacks Equity Research — Thu, 04 Oct 2012 00:23:01 Z

Health Canada recently approved InterMune, Inc. 's ( ITMN ) Esbriet (pirfenidone) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF) in adults. The company expects

French Reimbursement for Esbriet - Analyst Blog

Zacks Equity Research — Fri, 14 Sep 2012 01:15:01 Z

InterMune, Inc. ( ITMN ) recently announced that the Comite Economique des Produits de Sante (CEPS), the pricing committee of France, has granted reimbursement for InterMune's Esbriet

Positive RECAP for ITMN's Esbriet - Analyst Blog

Zacks Equity Research — Tue, 04 Sep 2012 23:34:41 Z

InterMune, Inc. ( ITMN ) recently presented data on Esbriet from the RECAP extension study at the 2012 Annual Congress of the European Respiratory Society (ERS). The open-label extension

Loss at ITMN Wider-Than-Expected - Analyst Blog

Zacks Equity Research — Tue, 24 Jul 2012 18:09:27 Z

InterMune Inc. ( ITMN ) posted second-quarter loss per share of 78 cents, wider than the year-ago loss of 70 cents and the Zacks Consensus Estimate of a loss of 17 cents. Higher costs

Loss at ITMN Wider-Than-Expected - Analyst Blog

Zacks Equity Research — Tue, 24 Jul 2012 18:09:03 Z

InterMune Inc. ( ITMN ) posted second-quarter loss per share of 78 cents, wider than the year-ago loss of 70 cents and the Zacks Consensus Estimate of a loss of 17 cents. Higher costs

Pre-Market Most Active for Jul 23, 2012 : NXY, GEN, BAC, TOT, BHP, NRG, QQQ, AAPL, SIRI, FB, ASML, ITMN

NASDAQ.com News — Mon, 23 Jul 2012 16:39:56 Z

The NASDAQ 100 Pre-Market Indicator is down -26.07 to 2,591.98. The total Pre-Market volume is currently 38,349,186 shares traded. The following are the most active stocks for the

ITMN Concludes Sale of Actimmune - Analyst Blog

Zacks Equity Research — Sat, 23 Jun 2012 00:12:59 Z

InterMune Inc. ( ITMN ) recently completed the sale of its rights to Actimmune to Vidara Therapeutics International Limited for $55 million plus royalties. Vidara is part of an international

InterMune to Sell Actimmune Rights - Analyst Blog

Zacks Equity Research — Tue, 22 May 2012 17:40:19 Z

InterMune Inc. ( ITMN ) recently announced that it has entered into an agreement with Vidara Therapeutics International Limited for the sale of its rights to Actimmune for $55

Pre-Market Most Active for Mar 15, 2012 : BAC, NOK, ITMN, AAPL, STM, RVSN, C, COF, ARMH, QQQ, NCT, CSCO

NASDAQ.com News — Thu, 15 Mar 2012 16:39:01 Z

The NASDAQ 100 Pre-Market Indicator is up 7.44 to 2,715.85. The total Pre-Market volume is currently 2,917,951 shares traded. The following are the most active stocks for the pre-market